NCT06253923 - Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI). | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

August 31, 2025

Conditions

Traumatic Brain Injury

Interventions

DRUG

Amantadine Hydrochloride

MR-301 is an I.V. formulation for the treatment of TBI. The active ingredient is amantadine hydrochloride (HCl).

DRUG

Placebo

The placebo for this study is 0.9% Sodium Chloride IV Solution.

Trial Locations (13)

Penn Presbyterian Medical Center, Philadelphia

Department of Neurology, Duke University School of Medicine, Durham

UF Health Heart and Vascular Hospital, Gainesville

Tampa General Hospital, Tampa

Wayne State University, Detroit

Medical College of Wisconsin, Milwaukee

Barnes Jewish Hospital, St Louis

McGovern Medical School, University of Texas Health Science Center, Houston

University of New Mexico Hospital, Albuquerque

Los Angeles General Medical Center, Los Angeles

UC Davis Medical Center, Sacramento

Maine Medical Center, Portland

Hackensack Meridian Health Jersey Shore University Medical Center, Neptune City